Marker Therapeutics (MRKR)
Develops non-genetically modified multi-antigen T-cell therapies for lymphoma, pancreatic cancer, AML, and MDS.
Something off on this page? Send us feedback.
Develops non-genetically modified, multi-antigen T-cell therapies, led by MT-601 for lymphoma and pancreatic cancer and MT-401-OTS for AML and MDS. Operates without approved products or product sales, relying on Baylor-licensed technology, external manufacturing, grants, and financing.
Develops non-genetically modified, multi-antigen recognizing T-cell therapies for blood cancers and pancreatic cancer. Its autologous MT-601 program is being studied in lymphoma after anti-CD19 CAR-T treatment or when CAR-T is unsuitable, with a separate planned pancreatic-cancer study; its donor-derived MT-401-OTS program is in early development for AML and MDS.
Operates as a lean, single research-and-development segment with no approved products or product-sale or licensing revenue. The platform's intellectual property is exclusively licensed from Baylor College of Medicine, which supplies current clinical material, while Cellipont Bioservices handles MT-601 technology transfer and manufacturing scale-up. Future commercialization or licensing would carry Baylor royalties; clinical advancement depends on trials, regulatory approvals, grant support, financing, and external manufacturing.
Company facts
No analyst consensus on record.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $11.3M · Total debt $0 · Total assets $14.6M · Shareholders' equity $12.2M
- Revenue
- $0
- Operating income
- −$2.6M
- Net income
- −$1.8M
No dividends on record.
| Institutions | 23.81% | 3.97M shares | |
|---|---|---|---|
| 35 holders · as of Jun 30, 2026 | |||
| Insiders | 1.95% | 325.4K shares | |
| 1 holder · as of Dec 26, 2024 | |||
| Other | 74.24% | 12.38M shares | |
| remainder | |||
16.67M company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Nea Management Company, LLCInstitution | 9.75% | 1.63M | as of Jun 30, 2026 |
Alyeska Investment Group, L.P.Institution | 7.68% | 1.28M | filed Nov 14, 2025 |
Blue Owl Capital Holdings LPInstitution | 3.32% | 554,250 | as of Jun 30, 2026 |
Vanguard Capital Management LLCInstitution | 2.56% | 426,169 | as of Jun 30, 2026 |
Aisling Capital Management LPInstitution | 1.95% | 325,370 | as of Jun 30, 2026 |
Insider tradesForm 4
No open-market trades in the last 12 months.
- Gilead Sciences
Yescarta sets the CD19 CAR-T standard in large B-cell lymphoma.
- Bristol-Myers Squibb
Breyanzi is a scaled CD19 CAR-T option in large B-cell lymphoma.
- Genmab (ADR)
Epkinly offers an off-the-shelf CD20xCD3 option in relapsed lymphoma.
- Allogene Therapeutics
Cema-cel pursues off-the-shelf CAR-T in large B-cell lymphoma.
- Caribou Biosciences
Vispa-cel advances genome-edited allogeneic CAR-T for B-cell lymphoma.
- Novartis (ADR)
Kymriah is an established CD19 CAR-T therapy for B-cell lymphoma.
- CRISPR Therapeutics
Zugo-cel is an investigational allogeneic CD19 CAR-T in blood cancers.
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Marker Therapeutics | $1.23 | +2.50% | $20.0M | — | — | 16.2 | −18.7% |
| Gilead Sciences | $152.59 | +1.35% | $186.93B | — | 16.8 | 6.1 | +10.2% |
| Bristol-Myers Squibb | $62.63 | +0.01% | $127.91B | 13.8 | 9.8 | 2.6 | +5.7% |
| Genmab (ADR) | $35.07 | +1.10% | $21.30B | 27.3 | 26.8 | 5.2 | +24.9% |
| Allogene Therapeutics | $1.71 | +0.89% | $583.3M | — | — | 125.7 | — |
| Caribou Biosciences | $1.34 | +2.69% | $128.9M | — | — | 12.8 | −43.8% |
| Novartis (ADR) | $141.16 | +0.13% | $267.96B | 21.3 | 15.0 | 4.8 | +0.9% |
| CRISPR Therapeutics | $57.94 | −0.66% | $5.63B | — | — | 420.1 | +1,041.4% |
| Median | 21.3 | 15.9 | 6.1 | +8.0% |